ライフサイエンスコーパス: autologous

1 Methods A total of 477 HCT recipients (236 autologous, 128 reduced-intensity allogeneic, 113 myeloa

2 ter they received intravitreal injections of autologous adipose tissue-derived "stem cells" at one su

3 romal lamina transplantation with or without autologous adipose-derived adult stem cell recellulariza

4 ntial benefits of its recellularization with autologous adipose-derived adult stem cells remains uncl

5 Autologous adipose-derived adult stem cells were obtaine

6 safety and efficacy of adding intra-arterial autologous adipose-derived MSCs into STK to standardized

7 Neither the depletion of autologous alpha-gal-specific IgG Ab nor the addition of

8 cognitive impairment was present in 18.7% of autologous and 35.7% of allogeneic HCT recipients.

9 Autologous and allogeneic hematopoietic stem cell transp

10 d in IVIg, but the reverse was true when the autologous and allogeneic IgG concentrations were augmen

11 However, phase I and II clinical trials with autologous and first-generation stem cells have yielded

12 ing psoriatic Mo-MDSC are unable to suppress autologous and heterologous CD8 T-cell proliferations, d

13 We compared the NAb activity against autologous and heterologous viruses between 10 participa

14 n = 30) adults and incubated together under autologous and nonautologous conditions.

15 scores were comparable between controls and autologous and reduced-intensity HCT recipients.

16 9-6.41%] implant, 9.89% (95% CI: 4.98-19.1%) autologous, and 26.7% (95% CI: 20.4-34.4%) no reconstruc

17 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-c

18 for the future development of personalized, autologous anticancer vaccines with broad applicability.

19 and granzyme B), and they were able to kill autologous antigen-loaded targets.

20 lutinin were able to present the antigens to autologous antigen-specific CD4(+) T cells in a major hi

21 ere capable of presenting vaccine antigen to autologous antigen-specific memory CD4(+) T cells ex viv

22 pendent conversion of endothelial cells into autologous authentic engraftable haematopoietic stem cel

23 domized comparison of safety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-d

24 ctor production and promote Ig production in autologous B cells.

25 express CD154, and induce IgE production by autologous B cells.

26 rrent status in generating and transplanting autologous beta-cells for diabetes cell therapy, highlig

27 cally compliant culture system, we show that autologous BK virus-specific T cell lines can be reliabl

28 patients demonstrated enhanced responses to autologous blasts in vitro, and primed CD56bright cells

29 a after ICH induction by injection of either autologous blood or collagenase.

30 An in vitro bovine liver model perfused with autologous blood via the portal vein at three flow rates

31 different HA content and particle size with autologous bone and empty defects, at two time points (6

32 apy, osteonecrotic defects were treated with autologous bone graft, which were simulated by using bon

33 It represents a promising alternative to autologous bone grafting, which is considered the curren

34 ndomized clinical trials, most of which used autologous bone marrow mononuclear cells, have found onl

35 eering the use of high-dose chemotherapy and autologous bone marrow transplantation in patients with

36 esigned to assess the safety and efficacy of autologous bone marrow-derived aldehyde dehydrogenase br

37 he responses after intracoronary infusion of autologous bone marrow-derived mononuclear cells (BMCs)

38 d standard treatment of the defect site with autologous bone tissue did not improve bone formation or

39 ostoperative complications after implant and autologous breast reconstruction in patients undergoing

40 ized for in vivo expansion of Breg cells and autologous Breg cell immunotherapy.

41 with improvements in deep sequencing of the autologous cancer have provided new insight into the mol

42 checkpoint modulators elicits potent in situ autologous cancer vaccination, resulting in an efficacio

43 Autologous CAR T cells are generated from the patient's

44 KEY POINTS: Autologous cardiac progenitor cell (CPC) therapy is a pr

45 ABSTRACT: Autologous cardiac progenitor cell therapy is a promisin

46 Clinical trials using autologous CD19-targeted T cells have shown remarkable p

47 To evaluate the safety and bioactivity of autologous CD34+ cell (CLBS10) intracoronary infusion in

48 rvest and were randomized 1:1 to receive (1) autologous CD34+ cells (minimum 10 mol/L+/-20% cells; N=

49 investigational therapy involved infusion of autologous CD34+ cells transduced with the elivaldogene

50 2, and used as antigen-presenting cells for autologous CD4(+) T cells (CD4(+) T cells coincubated wi

51 -moDCs strongly potentiated proliferation of autologous CD4(+) T cells and CD8(+) T cells and product

52 Cytotoxicity against HIV-infected autologous CD4(+) T cells strikingly correlated with rea

53 ate the safety and efficacy of administering autologous CD4(+) T cells that are genetically engineere

54 with differentially fluorescent dye-labeled autologous CD8(hCXCR5) and untransduced CD8 T cells and

55 ts their use in generation of cell pools for autologous cell replacement therapies.

56 cted endothelium holds promise for potential autologous cell therapies.

57 the swine were randomly assigned to receive autologous cell therapy (endothelial cells, n = 4) or co

58 of studies evaluating safety and efficacy of autologous cell therapy for intractable peripheral arter

59 quipoise may no longer be guaranteed because autologous cell therapy has the potential to modify the

60 ime would provide significant advantages for autologous, cell-based therapies in regenerative medicin

61 Generating abundant and functional autologous cells for transplantation in such a setting,

62 18-gauge hepatic core samples to 50 x 10(6) autologous cells per pig.

63 which are logistically more convenient than autologous cells.

64 sed the production of IL-2 and IFNgamma from autologous cells; a process mediated through increased p

65 nce of sputum autoantibodies against EPX and autologous cellular components.

66 he results of clinical studies investigating autologous cellular therapies in urological malignancies

67 Sipuleucel-T is an autologous cellular therapy for asymptomatic, or minimal

68 modified by the anti-FcmuR CAR, purged their autologous CLL cells in vitro without reducing the numbe

69 reparation of human saphenous vein (HSV) for autologous coronary and peripheral arterial bypass proce

70 ficiency virus type 1 (HIV-1) efficacy of an autologous dendritic cell (DC)-based HIV-1 vaccine loade

71 ivered intratumorally, including infusion of autologous dendritic cells and even tumor-reactive T lym

72 T cell clones downregulated the response of autologous effector T cells to IFX.

73 o quantified by measuring the suppression of autologous effector T-cell proliferation by Treg cell in

74 By sequencing autologous env, we determined key residues that triggere

75 und outcomes following genetically corrected autologous epidermal grafts in patients with RDEB.

76 long-term efficacy of genetically corrected autologous epidermal grafts.

77 scintigraphy performed with (99m)Tc-labeled autologous erythrocytes or historically with (99m)Tc-sul

78 ication of the pre-grafting expansion during autologous fat transplantation in breast reconstruction,

79 l cure compared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042).

80 fiscal consequence of hospital variation for autologous free flap breast reconstruction is unknown.

81 The mean cost for autologous free flap breast reconstruction was $22677 (i

82 ant cost variation among patients undergoing autologous free flap breast reconstruction.

83 at high risk for breast cancer and underwent autologous free flap breast reconstruction.

84 te factors that influence cost variation for autologous free flap breast reconstruction.

85 f scalable constructs that are vascularized, autologous, functional, implantable, cost-effective, and

86 novations centered around the development of autologous gene therapies targeting private somatic muta

87 Autologous gene therapy using a lentiviral vector is a v

88 hat solely neutralized pseudovirions bearing autologous GP1 provided enhanced neutralization of MACV

89 mplant group (difference, -3.8; P = .001) or autologous group (-2.2; P = .04), nor was physical well-

90 rapies, including immunoablation followed by autologous haematopoietic stem cell transplantation, mes

91 trial showed no benefit of mobilisation and autologous haematopoietic stem-cell transplantation (HSC

92 Autologous HCT is now the standard of care for patients

93 Cognitive functioning in autologous HCT recipients generally was spared.

94 ioning after reduced-intensity allogeneic or autologous HCT remains unclear.

95 9 and 2012 and received transplantation with autologous hematopoietic CD34+ cells that were modified

96 Autologous hematopoietic cell transplant (AHCT) for HIV-

97 Autologous hematopoietic stem cell transplantation (HSCT

98 Autologous hematopoietic stem cell transplantation (HSCT

99 ansfer of normal globin-producing genes into autologous hematopoietic stem cells (HSCs) are in clinic

100 ion of an antisickling beta-globin gene into autologous hematopoietic stem cells.

101 glioblastoma received 1 or more infusions of autologous HER2-CAR VSTs (1 x 106/m2 to 1 x 108/m2) with

102 Infusion of autologous HER2-CAR VSTs is safe and can be associated w

103 cted with 19 titanium meshes and particulate autologous-heterologous bone.

104 f complex tissues from hiPSCs using a single autologous hiPSCs as source and generates a range of str

105 esponses capable of blocking transmission of autologous HIV to the infant.

106 ic cell (DC)-based HIV-1 vaccine loaded with autologous HIV-1-infected apoptotic cells.

107 Gene therapy using autologous HSCs should avoid these limitations and thus

108 liciting the role of donor and host Tregs in autologous HSCT is not possible in humans due to the aut

109 rimary outcome was MG disease activity after autologous HSCT measured by frequency of emergency depar

110 Autologous HSCT using genetically corrected cells would

111 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant center

112 cells into humanized mice reconstituted with autologous human cord blood immune cells.

113 ecently developed humanized mouse model with autologous human immune and liver cells, human liver and

114 ptively transferred cells in the presence of autologous human immune cells prior to clinical use.

115 se findings demonstrate that the presence of autologous human immune cells supports the in vivo survi

116 tated peptides with high-affinity binding of autologous human leukocyte antigen (HLA) molecules.

117 ibody binding to swine RBC that is as low as autologous human RBC.

118 ted from knockout swine and to allogeneic or autologous human RBC.

119 Importantly, autologous human SCs could be transplanted into injured

120 ibute to their poor autoproteolysis, causing autologous immune stimulation upon necrotic exposure.

121 cross-reacted with host antigens, including autologous intestinal microbiota.

122 rast, the incidence of SSI was similar after autologous IR (9.8% [177 of 1799]), DR (13.9% [19 of 137

123 after implant IR and 1.11 [range, 0-6] after autologous IR) compared with women who did not have a co

124 after implant IR and 0.87 [range, 0-6] after autologous IR).

125 incidence of SSI and NIWCs after implant and autologous IR, DR, and SR breast procedures after mastec

126 iate into beta-cells and provide a source of autologous islets for cell replacement.

127 Interventions: Autologous keratinocytes isolated from biopsy samples co

128 nteers were randomized to a single standard, autologous, leukoreduced, packed red cell transfusion af

129 institutional animal care and use committee, autologous liver endothelial cells were grown from core

130 ents with cancer through the use of ACT with autologous lymphocytes has provided an opportunity to di

131 d found these cells could mediate killing of autologous lymphoma cells.

132 The combination of autologous mesenchymal stem cells (MSCs) and cardiac ste

133 6-month, phase 1 trial to determine whether autologous mesenchymal stem cells, applied in a bioabsor

134 Autologous mesenchymal stromal cells (MSC) treatments ha

135 hat is more logistically convenient than the autologous MSC treatment.

136 ence of safety of intra-arterial infusion of autologous MSCs in patients with RVD.

137 can be grown in large numbers in vitro, and autologous MSCs transfused into tuberculosis patients ha

138 interferon-gamma from co-cultures of DCs and autologous Mtb antigen-specific CD4(+) T cells.

139 studies showing that seeding scaffolds with autologous mucosa improves regeneration.

140 lls (iNSCs) have significant potential as an autologous, multifunctional cell therapy for stroke, whi

141 MM) patients displayed superior responses to autologous myeloma targets, and furthermore, CD56bright

142 , V3 immunogenicity was eliminated while the autologous NAb response was unchanged.IMPORTANCE Trimeri

143 e SOSIP.664 prototype, without affecting the autologous NAb response.

144 were able to induce regulatory T cells from autologous naive CD4(+) T cells.

145 For the analysis of polarization, DCs and autologous naive CD4+ T cells were cocultured.

146 us HSCT is not possible in humans due to the autologous nature of the intervention.

147 Autologous, NCT00968760; allogeneic, NCT01497184; long-t

148 d to bridge long, nonhealing nerve gaps, the autologous nerve graft (autograft), has several drawback

149 losely mimic the native Env spike can induce autologous neutralizing antibodies (NAbs) against relati

150 tive-like CZA97.012 SOSIP.664 trimers induce autologous neutralizing antibodies (NAbs) efficiently in

151 erior germinal center formation and enhanced autologous neutralizing antibodies against the neutraliz

152 a HIV-1 transmitted/founder (TF) Env induces autologous neutralizing antibodies that can not only neu

153 germinal center B cells and eliciting tier-2 autologous neutralizing antibodies.

154 ter formation, and the elicitation of tier-2 autologous neutralizing antibodies.

155 Autologous neutralizing antibody (nAb) responses and CD8

156 cades of investigation, it is now known that autologous neutralizing antibody responses and their sel

157 s comparable to HIV-1 in humans and elicited autologous neutralizing antibody responses typical of HI

158 and M1-oriented macrophages fully activated autologous NK cells.

159 Platelet-rich fibrin (PRF) is an autologous non-transfusional hemo-component with a high

160 Other reports, involving some types of autologous, nonocular cell sources, have been linked to

161 IFN-gamma and IL-17A cytokine production by autologous, NTHi-specific lung CD4(+) T cells, and cytok

162 Bilateral autologous (odds ratio 1.73, 95% confidence interval 1.0

163 We treated 3 patients with Ph(+) ALL with autologous or allogeneic (p190)BCR-ABL-specific CTLs.

164 ve genomic and/or epigenomic manipulation of autologous or allogeneic cells.

165 hat combined of intranodal administration of autologous or allogeneic DRibbles together with anti-OX4

166 with hematologic malignancies who underwent autologous or allogeneic HCT to inpatient palliative car

167 sion transplantation strategies using either autologous or allogeneic stem cells.

168 erentially fuse to TCR-activated T cells and autologous parent cells.

169 We demonstrate that autologous patient CD4(+) T cells internalize CLL-EVs co

170 but decreased with culture of HIV MDSC with autologous PBMCs.

171 ight main bronchus was closed by means of an autologous pericardial patch.

172 on days -5 and -4, followed by reinfusion of autologous peripheral blood stem cells; group E).

173 ase after induction treatment, with adequate autologous peripheral blood stem-cell collection, and wi

174 d adult monocyte-derived DCs cultured in 10% autologous plasma or in newborn cord, infant, adult, and

175 However, in the presence of autologous platelets, monocytes from older adults synthe

176 gineered extracellular matrix populated with autologous pluripotent cells can result in de-novo organ

177 ion and lower developmental competence, with autologous populations of mitochondrial isolate at ferti

178 e-AIT sera, the presence of heterologous and autologous post-AIT sera significantly reduced the aller

179 1.2 mg RSV in situ gel with a 1:1 mixture of autologous PRF and HA bone graft in the surgical treatme

180 lar Class II furcation defects compared with autologous PRF and HA bone graft placed after open-flap

181 Furcation defect treatment with autologous PRF combined with 1% ALN gel results in signi

182 e clinical and radiographic effectiveness of autologous PRF versus PRF + HA in treatment of IBDs in p

183 IBDs in 17 patients were treated either with autologous PRF with open flap debridement (OFD) or OFD a

184 ronic periodontitis were treated either with autologous PRF with open flap debridement (OFD+PRF) or O

185 Ninety IBDs were treated with autologous PRF with open-flap debridement (OFD), PRF + H

186 ed by EBV-infected cells, to B cell lines or autologous primary B lymphocytes also promoted specific

187 In situ agglutination of autologous RBCs was achieved by means of embedded reagen

188 lls persisted for an average of 201 days for autologous recipients and 51 days for allogeneic recipie

189 ing of the abdomen in patients who underwent autologous reconstruction (-13.4; P < .001).

190 rom 1998 to 2007 and who underwent immediate autologous reconstruction (n = 2637), immediate implant-

191 ruction, 20.5% with implants, and 20.7% with autologous reconstruction (P < 0.001).

192 Patients in the autologous reconstruction group had improved satisfactio

193 for baseline values, patients who underwent autologous reconstruction had greater satisfaction with

194 4; P = .035), whereas patients who underwent autologous reconstruction had increased pain interferenc

195 ear after mastectomy, patients who underwent autologous reconstruction were more satisfied with their

196 Surgeon B believed that autologous reconstruction would yield the best long-term

197 women undergoing immediate implant-based or autologous reconstruction.

198 eeks of refrigerated storage, transfusion of autologous red cells to healthy human volunteers increas

199 or chemotherapy but not in those undergoing autologous SCTs.

200 omorbidities and possible causes of CSU, and autologous serum skin test (ASST) response.

201 whether such effects could be reproduced in autologous settings by TCR gene-engineered lymphocytes.

202 Deficiency of autologous skin for reconstruction of severe wounds is a

203 llogeneic cells show several advantages over autologous sources: they can be produced in large quanti

204 ributed in vitro to tumor cell resistance to autologous-specific CTL and in vivo to the in situ recru

205 d toward consolidative high-dose therapy and autologous stem cell rescue with improving long-term sur

206 RATIONALE: Autologous stem cell therapy using human c-Kit(+) cardia

207 py among 235 patients initially treated with autologous stem cell transplant (ASCT) at Mayo Clinic.

208 Utilization of autologous stem cell transplant (ASCT) was similar acros

209 The addition of an autologous stem cell transplant before cART withdrawal a

210 odgkin's lymphoma who previously received an autologous stem cell transplant or two previous multiage

211 native to platinum-based chemotherapy before autologous stem cell transplant.

212 e inhibitors (91%), alkylating agents (91%), autologous stem cell transplantation (78%), thalidomide

213 rge B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation (ASCT) or having re

214 se induction and up-front consolidation with autologous stem cell transplantation (ASCT) remain contr

215 patients (Deauville score </=2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-

216 lassification, and patients could proceed to autologous stem cell transplantation (ASCT).

217 eceiving systemic chemotherapy or subsequent autologous stem cell transplantation for treatment of he

218 actory response, a consolidation by means of autologous stem cell transplantation may offer a greater

219 select patients with chemosensitive disease, autologous stem cell transplantation should be considere

220 ne therapy) or relapsed at </=12 months from autologous stem cell transplantation.

221 or younger who are potential candidates for autologous stem cell transplantation.

222 incorporated into intensive strategies with autologous stem cell transplantation.

223 atients were permitted to come off study for autologous stem cell transplantation.

224 located between whole-brain radiotherapy and autologous stem cell transplantation.

225 KEY POINTS: While autologous stem cell-based therapies are currently being

226 aged CPCs, which may impact future design of autologous stem cell-based therapies.

227 enetic disorders involves transplantation of autologous stem cells that have been genetically correct

228 ne rejections and responses of allogeneic or autologous stem cells.

229 eted sequencing on cryopreserved aliquots of autologous stem-cell products from 401 patients who unde

230 egimens including cytarabine, rituximab, and autologous stem-cell transplant (ASCT).

231 relapsed or refractory myeloma undergoing an autologous stem-cell transplant (ASCT).

232 e myeloma who were not planned for immediate autologous stem-cell transplant.

233 ance therapy or to undergo observation after autologous stem-cell transplantation (120 patients per g

234 rpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated

235 We hypothesized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma

236 104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investig

237 y of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alter

238 obust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT).

239 refractory (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT).

240 Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce

241 cal Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab ved

242 ecommended for pediatric patients undergoing autologous stem-cell transplantation and for adult and p

243 ontrolled trials, adult patients who undergo autologous stem-cell transplantation at experienced cent

244 High-dose chemotherapy plus autologous stem-cell transplantation has been the standa

245 is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognos

246 mib, and dexamethasone (RVD) with or without autologous stem-cell transplantation, followed by lenali

247 after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have rela

248 rly for patients who are eligible to receive autologous stem-cell transplantation.

249 Autologous substitutes can provide additional coverage,

250 , functional characterization of LITRs in an autologous system.

251 ular chimera), engineered to express several autologous T cell epitopes and sequences derived from th

252 using a Theileria-transformed cell line and autologous T cells from Theileria-infected cattle.

253 Therapy with genetically modified autologous T cells has shown great promise in cancer the

254 atient-derived human melanoma cells by their autologous T cells in vitro and potentiates responses to

255 We used autologous T cells that express a CD19-directed CAR (CTL

256 psed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retrov

257 tetanus toxoid complexes and cocultured with autologous T cells.

258 ected with NTHi in vitro and cocultured with autologous T cells.

259 MDSCs were suppressive of autologous T-cell responses as evidenced by reduced T-ce

260 ompare their functional profile with that of autologous TH2 cells.

261 ) are being pursued as a source of cells for autologous therapies, many of which will be aimed at age

262 Autologous thrombus was administered from below the filt

263 ct on the quantity, quality, and kinetics of autologous tier 2 nAb development.

264 andidates elicit predominantly tier 1 and/or autologous tier 2 virus neutralizing antibody (NAb) resp

265 -1 neutralizing antibodies and induce robust autologous tier-2 neutralization, unlike a first-generat

266 re done to procure tumour tissue to generate autologous TIL cultures, which then underwent large scal

267 followed by a single intravenous infusion of autologous TILs and high-dose interleukin-2 [720 000 IU/

268 first report describing adoptive transfer of autologous TILs to mediate objective tumour regression i

269 ost defense, but its dysregulation can cause autologous tissue injury.

270 Women underwent implant-based or autologous tissue reconstruction.

271 SOSIP.4mut elicited a higher ratio of tier 2 autologous titers versus tier 1 V3-sensitive titers than

272 time, indicating the transition from narrow autologous to broad heterologous neutralization over tim

273 fractory to both; (31 [70%]) had received an autologous transplant, and (30 [62%]) had high-risk cyto

274 les from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-H

275 itical aspects of vascular repair, including autologous transplantation of bone marrow-derived stem c

276 Autologous transplantation of hematopoietic stem and pro

277 ctions of impaired IP-DPSCs, suggesting that autologous transplantation of IFN-gamma-accelerated IP-D

278 cells (HSPCs) from FA patients, either after autologous transplantation or infusion into immunodefici

279 Autologous transplantation should be considered in young

280 it from early treatment intensification with autologous transplantation, as indicated by the possibil

281 rative medicine, given their feasibility for autologous transplantation.

282 py has been developed as a method to perform autologous transplantations of a patient's own stem cell

283 Surgeon B contrasted the pros and cons of an autologous transverse rectus abdominis muscle flap recon

284 , we used viable human lung tumor slices and autologous tumor antigen-specific T-lymphocyte clones to

285 phocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting that cells derived fr

286 mpromised their functional activities toward autologous tumor cells.

287 dministration of dendritic cells pulsed with autologous tumor lysate combined with cyclophosphamide i

288 In response to autologous tumor, EECs upregulated CD107a, produced IL2

289 ) trials to date have focused on transfer of autologous tumor-specific cytotoxic CD8(+) T cells; howe

290 sought to determine if adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs) could

291 igens, and in some cases directly recognized autologous tumour.

292 ut, elicited a significantly higher ratio of autologous versus V3-directed neutralizing antibody resp

293 P = 0.017 for NL4-3) and marginally against autologous virus (P = 0.054).

294 e, together with evidence of contemporaneous autologous virus neutralization, supports the proposal t

295 ciency have had relative success; the use of autologous virus-specific cytotoxic T cells has proved e

296 nvs) induced neutralizing Abs against Tier 2 autologous viruses expressing cognate envelope (Env).

297 Monotherapy with autologous VSTs specific for cytomegalovirus, Epstein-Ba

298 , 1,632 patients (n = 1,139 implant, n = 493 autologous) were included; 1,183 (72.5%) responded to 1-

299 g preservation up to 24 hours (24H) by using autologous whole donor blood circulating within an ex vi

300 The use of an autologous whole donor blood perfusate allowed 24H of pr